Division of Immunohematology and Transfusion Medicine, Department of Oncology-Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy.
Thromb Res. 2012 Apr;129 Suppl 1:S132-6. doi: 10.1016/S0049-3848(12)70033-6.
Microparticles (MP) are shed from the surface of activated or apoptotic blood cells and their levels in plasma reflect a balance between cell stimulation, proliferation, and death. MP production occurs through vesiculation of cell membranes, and involves cytoskeletal changes and a shift in the normal phospholipid asymmetry. The expression on the majority of MP of the anionic phosphatidylserine (PS) is responsible for the capacity of MP to support blood coagulation activation. In some cases, PS expression is also associated, in the same MP, with the presence of active Tissue Factor, the main activator of blood coagulation. Elevation in plasma levels of MP have been described in numerous clinical conditions, most of which also associated with an increased thrombotic risk. Particularly, MP have been found to be increased in both solid and hematological malignancies, including myeloproliferative neoplasms. A role of MP in tumor progression has been suggested by both in vitro and in vivo studies. Evidence exists that MP of platelet origin are the main players in this process, being rich in pro-angiogenic factors. The utility of measuring MP as a diagnostic and prognostic marker is currently a subject of intense investigation. The possibility to inhibit MP production by pharmacological interventions represents a future challenge.
微粒(MP)从活化或凋亡的血细胞表面脱落,其在血浆中的水平反映了细胞刺激、增殖和死亡之间的平衡。MP 的产生通过细胞膜的囊泡化发生,涉及细胞骨架的变化和正常磷脂不对称性的转变。大多数 MP 上阴离子磷脂酰丝氨酸(PS)的表达负责 MP 支持血液凝固激活的能力。在某些情况下,PS 表达也与同一 MP 中存在的活性组织因子(血液凝固的主要激活剂)相关。在许多临床情况下,包括骨髓增生性肿瘤在内的大量实体瘤和血液系统恶性肿瘤中,已发现血浆 MP 水平升高,并且这些情况通常与血栓形成风险增加相关。特别地,已经发现血小板来源的 MP 在肿瘤进展中起重要作用,它们富含促血管生成因子。体外和体内研究均表明 MP 在肿瘤进展中起作用。目前,作为诊断和预后标志物测量 MP 的效用是一个研究热点。通过药理干预抑制 MP 产生的可能性代表了未来的挑战。